恩替卡韦联合康艾注射液治疗原发性肝癌的临床疗效观察

Clinical Efficacy of Entecavir Combined With Kang'ai Injection in the Treatment of Primary Liver Cancer

目的探究恩替卡韦联合康艾注射液治疗原发性肝癌的临床疗效。方法随机纳入本院收治的80例原发性肝癌患者作为观察对象,采用信封法进行分组(观察组和对照组),每组n=40,对照组患者使用康艾注射液治疗,观察组患者在对照组的基础上结合使用恩替卡韦。分别观察两组患者的治疗效果、肝功能指标改善情况、不良反应发生情况等。结果观察组总缓解率65.00%,明显高于对照组的37.50%,两组比较差异具有统计学意义(P <0.05),在肝功能的观察,观察组的总胆红素等相关指标均要明显优于对照组,且观察组的不良反应率明显低于对照组,两组比较差异具有统计学意义(P <0.05)。结论恩替卡韦联合康艾注射液治疗原发性肝癌的临床效果较好,不仅能够提升患者治疗的有效率,改善患者的肝功能情况,并且在治疗后的跟踪随访中,患者出现不良反应的情况也较少,治疗的安全性和可行性高。

Objective To explore the clinical efficacy of entecavir combined with Kangai injection in the treatment of primary liver cancer. Methods 80 patients with primary liver cancer admitted by our hospital were randomly selected as the objects of observation, and were divided into groups by envelope method. n=40 for each group. Patients in the control group were treated with Kang’ai injection, while patients in the observation group were treated with entecavir on the basis of the control group. The therapeutic effect, improvement of liver function index and adverse reaction of the two groups were observed respectively. Results The total remission rate of the observation group was 65.00%, which was significantly higher than that of the control group of 37.50%, the difference between the two groups was statistically significant (P < 0.05). In the observation of liver function, the total bilirubin and other related indicators of the observation group were significantly better than those of the control group, and the adverse reaction rate of the observation group was significantly lower than that of the control group, the difference between the two groups was statistically significant (P < 0.05). Conclusion Entecavir combined with Kang’ai injection has a good clinical effect in the treatment of primary liver cancer, which can not only improve the efficiency of patients' treatment and improve the liver function of patients, but also reduce adverse reactions in patients during follow-up after treatment, which is of high safety and feasibility.